Login
$NXGL
$3.93 +$0.05 (1.29%) Live

Company Executives

Officer Age In this role Source
Brian J. Kieser Also a director
Interim CEO
Title from the Form 4 dated Nov 10, 2026
59 Not stated
Ian Blackman
Chief Financial Officer
58 Since 2026
this year

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Jun 9, 2026 · updated by the 8-K of Aug 21, 2026

Directors
3
serving now
Average tenure
1.7 years
from year joined
CEO also chairs the board
No
Steven Glassman
Director Age On board Committees 2025 pay Source
Steven Glassman
61 2021
5 years
Audit Committee Compensation Committee · Chair Nominating and Corporate Governance Committee
$85,883
Brian J. Kieser
59 2026
this year
None stated Not stated
Kevin M. Harris
51 2026
this year
None stated Not stated
  • An 8-K filed Jul 2, 2026 says Scott Henry left the board; they could not be matched to a director above.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

5 disclosed in the proxy filed Jun 9, 2026
Sequence LifeScience, Inc.
Indirect sole owner is Brian J. Kieser, our Chief Executive Officer and a director appointed May 6, 2026
$5,500,000

Sequence purchased April Notes and April Warrants in the April 2026 Financing

Three members of our Board and two executive officers
Directors and executive officers of the Company
$125,000

Directors and executive officers invested in the April 2026 Financing on the same terms as unaffiliated Buyers

Brian J. Kieser
Director appointed to our Board on May 6, 2026
$1,000,000
Between May 11, 2026 and May 14, 2026

Mr. Kieser purchased May Notes and May Warrants in the May 2026 Financing

Mr. Levy
Director of the Company
$60,000
Between May 11, 2026 and May 14, 2026

Mr. Levy purchased May Notes and May Warrants in the May 2026 Financing

Mr. Henry
Director of the Company
$25,000
Between May 11, 2026 and May 14, 2026

Mr. Henry purchased May Notes and May Warrants in the May 2026 Financing

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support